Setting the TEMPO: What have we learned about D1/D5 dopamine stimulation in Parkinson’s disease?
MDS PodcastShow Notes
Dr. Divyani Garg speaks with Dr. Hubert H. Fernandez about tavapadon, a once-daily selective dopamine D1/D5 receptor agonist, and what the TEMPO clinical development program tells us about its potential role in Parkinson’s disease (PD). They discuss the rationale for D1/D5 stimulation, findings from other TEMPO programs, the magnitude and clinical meaning of the motor benefit, flexible dosing, and the important tolerability and discontinuation findings from TEMPO-2. The conversation also explores where tavapadon might fit relative to levodopa and conventional D2/D3 dopamine agonists, and its potential role across different stages of PD.
Read the article.
More from MDS Podcast
Dr. Mitra Afshari discusses with Dr. Raul Martínez-Fernández recent advances in MRI-guided focused ultrasound for essential tremor and Parkinson’s disease, including improvements in safety and efficacy, its relationship with deep brain stimulation, and emerging neuromodulation approaches.
Dr. Eduardo de Pablo-Fernández discusses with Dr. Samuel Kim recent advances in Huntington’s disease, including genetic mechanisms, emerging biomarkers, and the potential of huntingtin-lowering therapies and gene therapy.
Dr. Eduardo de Pablo-Fernández discusses with Prof. Tom Foltynie emerging disease-modifying and restorative treatments for Parkinson’s disease, including recent clinical trial findings and promising therapeutic approaches.
Ms. Nicole Duff discusses with Dr. Alison Yarnall the prevalence and impact of frailty in Parkinsonism, including how it is identified and measured and its implications for clinical trials and patient care.
Dr. Jerome Honnorat sits down with host Dr. Divyani Garg at the 2026 MDS international Congress to review the most recent advancements in autoimmune movement disorders.